Continuous lavage with voriconazole CONTROLS progression in moderate and severe fungal keratitis
The study entitled "Continuous voriconazole lavage in managing moderate and severe fungal keratitis: a randomized controlled trial" by Gong et and the team has described the role of continuous lavage with voriconazole in controlling the progression of moderate and severe fungal keratitis. It does not cause damage to the corneal epithelium, stroma or conjunctiva.
This study is published in Graefe's Archive for Clinical and Experimental Ophthalmology.
It is already known that continuous lavage with antibiotics is proven to be SUCCESSFUL for managing resistant bacterial keratitis. This is because it increases the drug concentration in the cornea.
The main purpose of this study was to assess the effectiveness and safety of continuous lavage with 1% voriconazole (CL) for moderate and severe fungal keratitis.
The researchers randomized thirty-one patients receiving topical eye drops either alone (T) or combined with continuous 1% voriconazole lavage (CL-T) and measured the cure rate at three months as the primary outcomes.
The secondary outcomes were the 6-day efficacy, 3-day infiltration size and depth, hypopyon height, central corneal thickness (CCT), epithelial defect size, and subject feelings and clinical signs assessment scores.
At three months, the cure rate was comparable between the groups in patients with moderate fungal keratitis (66.7% vs 62.5%). Nearly four cases constituting 44.4 %, are the severe cases in the CL-T group healed successfully, while none in the T group; this difference was insignificant (small sample size).
After six days, the percentage of patients with "worsened" ulcers in the CL-T group was lower when compared to that of the T group, recorded as 0% vs 31%.
After three days, the infiltration size, infiltration depth, and hypopyon height in the CL-T group were smaller than in the T group. There was no difference between groups in CCT, epithelial defect size, subject feelings scores, or clinical signs scores.
They said, "In our research, we found that CL is an effective and safe adjuvant method for controlling the progression of moderate and severe fungal keratitis."
Further reading:
https://link.springer.com/article/10.1007/s00417-022-05969-z
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.